Porcilis AR-T DF

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

protein dO (non-toxic deletion derivative of Pasteurella multocida dermonecrotic toxin), inactivated Bordetella bronchiseptica cells

Available from:

Intervet International BV

ATC code:

QI09AB04

INN (International Name):

adjuvanted vaccine against progressive atrophic rhinitis in piglets

Therapeutic group:

Pigs (gilts and sows)

Therapeutic area:

Immunologicals for suidae

Therapeutic indications:

For the reduction of clinical signs of progressive atrophic rhinitis in piglets by passive oral immunisation with colostrum from dams actively immunised with the vaccine.

Product summary:

Revision: 6

Authorization status:

Authorised

Authorization date:

2000-11-16

Patient Information leaflet

                                B. PACKAGE LEAFLET
15
PACKAGE LEAFLET
PORCILIS AR-T DF SUSPENSION FOR INJECTION FOR PIGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis AR-T DF suspension for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 2 ml contains:
Active substances:
- Protein dO (non-toxic deletion derivative of
_Pasteurella _
_multocida _
dermonecrotic toxin)
≥
6.2 log2 TN titre
1
- Inactivated
_Bordetella bronchiseptica_
cells.
≥
5.5 log2 Aggl. titre
2
1
Mean toxin neutralising titre obtained after repeated vaccination of a
half dose in rabbits.
2
Mean agglutination titre obtained after a single vaccination of a half
dose in rabbits
Adjuvant:
dl-α-tocopherol acetate
150 mg
Excipient:
Formaldehyde
≤1 mg
4.
INDICATION(S)
For the reduction of clinical signs of progressive atrophic rhinitis
in piglets by passive oral
immunisation with colostrum from dams actively immunised with the
vaccine.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
A mean transient increase in body temperature of 1.5°C, in some pigs
up to 3 °C, which could lead to an
abortion, can generally be measured on the day of vaccination or the
following day. Reduced activity and
lack of appetite on the day of vaccination very commonly occurs and/or
a transient swelling (max
16
diameter: 10 cm) for up to two weeks may arise at the site of
injection. In very rare cases other immediate
hypersensitivity reactions, e.g. vomiting, dyspnoea and shock, may
occur.
If you notice any serious effects or other effects not mentioned in
this package leaflet, please inform
your veterinary surgeon.
7.
TARGET SPECIES
Pigs (sows and gilts).
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Administer one dose of 2 ml by intramuscular injectio
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis AR-T DF suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
ACTIVE SUBSTANCES:
- Protein dO (non-toxic deletion derivative of
_Pasteurella _
_multocida _
dermonecrotic toxin)
≥
6.2 log2 TN titre
1
- Inactivated
_Bordetella bronchiseptica_
cells
≥
5.5 log2 Aggl. titre
2
1
Mean toxin neutralising titre obtained after repeated vaccination of a
half dose in rabbits.
2
Mean agglutination titre obtained after a single vaccination of a half
dose in rabbits
ADJUVANT:
dl-α-tocopherol acetate
150 mg
EXCIPIENT:
Formaldehyde
≤1 mg
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (sows and gilts).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the reduction of clinical signs of progressive atrophic rhinitis
in piglets by passive oral immunisation
with colostrum from dams actively immunised with the vaccine.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Vaccinate only healthy animals
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL PRODUCT TO ANIMALS
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the
2
label to the physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A mean transient increase in body temperature of 1.5 °C, in some pigs
up to 3 °C, which could lead to an
abortion, can generally be measured on the day of vaccination or the
following day. Reduced activity and
lack of appetite on the day of vaccination very commonly occurs and/or
a transient swelling (max
diameter: 10 cm) for up to two weeks may arise at the site of
injection. In very rare cases other immediate
hypersensitivity reactions, e.g. vomiting, dyspnoea and shock, may
occur.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Can be use
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-05-2014
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-05-2014
Public Assessment Report Public Assessment Report Bulgarian 20-12-2011
Patient Information leaflet Patient Information leaflet Spanish 05-05-2014
Public Assessment Report Public Assessment Report Spanish 20-12-2011
Patient Information leaflet Patient Information leaflet Czech 05-05-2014
Public Assessment Report Public Assessment Report Czech 20-12-2011
Patient Information leaflet Patient Information leaflet Danish 05-05-2014
Public Assessment Report Public Assessment Report Danish 20-12-2011
Patient Information leaflet Patient Information leaflet German 05-05-2014
Public Assessment Report Public Assessment Report German 20-12-2011
Patient Information leaflet Patient Information leaflet Estonian 05-05-2014
Public Assessment Report Public Assessment Report Estonian 20-12-2011
Patient Information leaflet Patient Information leaflet Greek 05-05-2014
Public Assessment Report Public Assessment Report Greek 20-12-2011
Patient Information leaflet Patient Information leaflet French 05-05-2014
Public Assessment Report Public Assessment Report French 20-12-2011
Patient Information leaflet Patient Information leaflet Italian 05-05-2014
Public Assessment Report Public Assessment Report Italian 20-12-2011
Patient Information leaflet Patient Information leaflet Latvian 05-05-2014
Public Assessment Report Public Assessment Report Latvian 20-12-2011
Patient Information leaflet Patient Information leaflet Lithuanian 05-05-2014
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-05-2014
Public Assessment Report Public Assessment Report Lithuanian 20-12-2011
Patient Information leaflet Patient Information leaflet Hungarian 05-05-2014
Summary of Product characteristics Summary of Product characteristics Hungarian 05-05-2014
Public Assessment Report Public Assessment Report Hungarian 20-12-2011
Patient Information leaflet Patient Information leaflet Maltese 05-05-2014
Public Assessment Report Public Assessment Report Maltese 20-12-2011
Patient Information leaflet Patient Information leaflet Dutch 05-05-2014
Public Assessment Report Public Assessment Report Dutch 20-12-2011
Patient Information leaflet Patient Information leaflet Polish 05-05-2014
Public Assessment Report Public Assessment Report Polish 20-12-2011
Patient Information leaflet Patient Information leaflet Portuguese 05-05-2014
Summary of Product characteristics Summary of Product characteristics Portuguese 05-05-2014
Public Assessment Report Public Assessment Report Portuguese 20-12-2011
Patient Information leaflet Patient Information leaflet Romanian 05-05-2014
Public Assessment Report Public Assessment Report Romanian 20-12-2011
Patient Information leaflet Patient Information leaflet Slovak 05-05-2014
Public Assessment Report Public Assessment Report Slovak 20-12-2011
Patient Information leaflet Patient Information leaflet Slovenian 05-05-2014
Summary of Product characteristics Summary of Product characteristics Slovenian 05-05-2014
Public Assessment Report Public Assessment Report Slovenian 20-12-2011
Patient Information leaflet Patient Information leaflet Finnish 05-05-2014
Public Assessment Report Public Assessment Report Finnish 20-12-2011
Patient Information leaflet Patient Information leaflet Swedish 05-05-2014
Public Assessment Report Public Assessment Report Swedish 20-12-2011
Patient Information leaflet Patient Information leaflet Norwegian 05-05-2014
Summary of Product characteristics Summary of Product characteristics Norwegian 05-05-2014
Patient Information leaflet Patient Information leaflet Icelandic 05-05-2014
Summary of Product characteristics Summary of Product characteristics Icelandic 05-05-2014
Patient Information leaflet Patient Information leaflet Croatian 05-05-2014